IMVT — Immunovant Inc
NASDAQ · Healthcare · Biotechnology
$43.49
+$0.17 (+0.39%)
Immunovant Inc (IMVT) is a biotechnology company listed on NASDAQ. It is led by Eric Venker M.D., Pharm.D., based in 320 West 37th Street, New York, NY, United States, 10018, with about 362 employees. Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Net income was -$126.5M. IMVT currently screens at market cap $2.90B.
Use this IMVT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMVT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMVT SEC filings page. Lician reads the product cache first so this HTML stays unique to Immunovant Inc even when a live quote feed is slow.
About Immunovant Inc
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for graves' disease and thyroid eye disease. The company has a license agreement with HanAll Biopharma Co., Ltd. for the rights of intellectual property relating to IMVT-1402 and batoclimab. Immunovant, Inc. was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Key Statistics
Market Cap
$2.90B
Volume
277,324
Previous Close
$43.32
Day Range
$43.37 – $44.50
EPS
-$2.73
Revenue
$0.00
Net Income
-$413.84M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
362
IMVT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$413.84M | -$259.34M | -$210.96M | -$156.73M |
| EPS (Diluted) | -$2.73 | -$1.88 | -$1.71 | -$1.43 |
Total Assets
$776.22M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$713.97M
Operating Cash Flow
-$375.87M
Free Cash Flow
$0.00
Immunovant Inc Company Information
- CEO & Director
- Eric Venker M.D., Pharm.D.
- Headquarters
- 320 West 37th Street, New York, NY, United States, 10018
- Website
- immunovant.com
- Phone
- 917 580 3099
- IPO / Founded
- 2019-06-21
- Sector
- Healthcare
- Industry
- Biotechnology